328 results about "Respiratory syncytial virus (RSV)" patented technology

A vector comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter is described. Such vector may be used to produce an RNA transcript which may be used to immunize a host, including a human host, to protect the host against disease caused by paramyxovirus, particularly respiratory syncytial virus, by administration to the host.

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

The present invention relates to a nucleic acid molecule, which codes for the F-protein of the respiratory syncytial virus (RSV) or a fragment thereof, for the expression in a human cell environment of codon optimized variants of said nucleic acid molecule, vectors and compositions comprising said nucleic acid molecules and the use thereof as vaccines and polypeptides coded by the nucleic acid molecules and method for the production thereof.

The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.

There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding.

The invention discloses a method for simultaneously detecting twelve kinds of common respiratory viruses. According to the method, primers and probes are designed according to gene conservative areas of the twelve kinds of common respiratory viruses, namely influenza A virus, influenza B virus, influenza C virus, parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, rhinovirus, Bocavirus, adenovirus, coronavirus, metapneumovirus and respiratory syncytial virus, nucleic acid fragments of samples to be measured are extracted for amplifying, and finally, the samples are separated by using a capillary electrophoresis method. The method disclosed by the invention has the advantages of low required sample size, high sensitivity and accuracy, good specificity and low cost; the defects that the conventional single tube multiplex fluorescence PCR (Polymerase Chain Reaction) detection primers are difficult to design, and multicolor fluorescence mutually intervenes and is not easy to part are overcome, the defects that a chip detection method is tedious in operation, high in detection cost and the like are also overcome, and a new method is provided for screening the respiratory viruses.

The invention provides a kit for nucleic acid combined detection of the influenza virus A, the influenza virus B and the respiratory syncytial virus. The kit comprises RT-PCR reaction liquid, an RT-PCR enzyme mixture, a respiratory virus primer probe, internal reference, negative contrast, clinical positive contrast and strong positive contrast. The one-step RT-PCR reaction can be directly conducted on the well-extracted respiratory virus nucleic acid, the influenza virus A, the influenza virus B and the respiratory syncytial virus in a sample can be detected in a classified and qualitative mode, the gene of the internal reference serves as the internal contrast, and contamination is prevented through UNG enzymes. The kit is simple in one-step amplification method, short in procedure, easy and convenient to operate, capable of preventing contamination, high in detection result specificity, high in sensitivity, clear in result, high in credibility, and capable of being used for qualitatively authenticating and detecting the influenza virus A, the influenza virus B and the respiratory syncytial virus in a human nose pharynx-mop sample.

The invention belongs to the medical technical field and discloses the application of high-purity in the preparation of antibacterial medicine, antiviral medicine and other medicines. The invention proves the antipyretic, anti-inflammation, immunity enhancement, antibacterial and anti-virus effects of high-purity forsythiaside through the following experiments: (1) the experiment that high-purity forsythiaside has antipyretic effect on fever rats; (2) the experiment that high-purity forsythiaside inhibits xylene-induced mice ear edema, xylene-reduced capillary permeability of mice; (3) the experiment that high-purity forsythiaside increases carbon clearance ability of mice and increases the lymphocyte transformation rate; (4) the experiment that high-purity forsythiaside has vitro anti-influenza A type virus effect and in-vivo anti-respiratory syncytial virus effect; (5) the experiment that high-purity forsythiaside has vitro inhibition effects on beta-hemolytic streptococcus, staphylococcus aureus, streptococcus viridans and staphylococcus epidermidis.

Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

The invention discloses a hybridomas cell strain with preserving number at CGMCC 1546, anti-respiratory syncytial virus N protein monoclone antibody and respiratory syncytial virus detecting agent box (colloidal gold method), which can detects the respiratory syncytial virus with high specificity, sensibility and accuracy to be preserved and transported conveniently for clinical and domestic usage with industrial property.

The present disclosure relates to a real-time fluorescence multiplex PCR primer probe for seven common respiratory system influenza virus pathogens and a kit. Seven influenza viruses are influenza A virus, influenza B virus, parainfluenza virus type I, parainfluenza virus type II, parainfluenza virus type III, respiratory syncytial virus and adenovirus. The present disclosure also provides a kit for multiplex fluorescence quantitative PCR detection of the seven influenza viruses, and the kit includes the primer probe set. The kit significantly improves the sensitivity, specificity, and simplicity of detection of the common respiratory system pathogens.

The invention provides an immune detection reagent for detecting respiratory syncytial virus and a corresponding reagent box. The immune detection reagent comprises anti-respiratory syncytial virus monoclonal antibody 1 as peridium antibody, anti-respiratory syncytial virus monoclonal antibody 2 as biotin labeling antibody and avidin-HRP (horseradish peroxidase). The invention also provides a method for detecting the respiratory syncytial virus by applying the immune detection reagent or the reagent box. The method has relatively high sensitivity and specificity and is easy to clinically use.

The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or other ion-exchange matrix column and eluting the protein using mild salt treatment. The F, G and M proteins, formulated as immunogenic compositions, are safe and highly immunogenic and protect relevant animal models against respiratory syncytial virus.

The invention discloses a mycobacterium tuberculosis TB10.4-F1 fusion protein vaccine and a preparation method thereof. The preparation method comprises the following steps of: connecting the mycobacterium tuberculosis TB10.4 protein gene with the F1 protein gene of respiratory syncytial virus protein, transferring into a colibacillus expressing strain, inducing by IPTG (isopropyl beta-D-1-thiogalactopyranoside) to express the TB10.4-F1 fusion protein, and acquiring the protein with higher purity by metal ion affinity chromatography. The fusion protein has stronger immunogenicity, can excite more balanced Th1/Th2 immune response, and can prevent infections of the mycobacterium tuberculosis and the respiratory syncytial virus.